320 Views | 429 Downloads
Corresponding authors: Mark Caulfield (m.j.caulfield@qmul.ac.uk) and Paul Elliott (p.elliott@imperial.ac.uk).
See publication for full list of authors.
See publication for full list of author contributions.
All authors critically reviewed and approved the final version of the manuscript.
K.W. is a Commercial partnerships manager for Genomics England, a UK Government Company.
M.A.N. consults for Illumina Inc, the Michael J. Fox Foundation and University of California Healthcare among others.
A.S.B. has received grants outside of this work from Merck, Pfizer, Novartis, AstraZeneca, Biogen and Bioverativ and personal fees from Novartis.
J.DA. has the following competing interests: Pfizer Population Research Advisory Panel (grant), AstraZeneca (grant), Wellcome Trust (grant), UK Medical Research Council (grant), Pfizer(grant), Novartis (grant), NHS Blood and Transplant(grant), National Institute of Health Research(grant), UK MEDICAL RESEARCH COUNCIL(grant), BRITISH HEART FOUNDATION(grant),UK NATIONAL INSTITUTE OF HEALTH RESEARCH (grant), EUROPEAN COMMISSION (grant), Merck Sharp and Dohme UK Atherosclerosis (personal fees), Novartis Cardiovascular and Metabolic Advisory Board (personal fees), British Heart Foundation (grant), European Research Council (grant), Merck (grant).
B.M.P. serves on the DSMB of a clinical trial funded by Zoll LifeCor and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson.
M.J.C. is Chief Scientist for Genomics England, a UK Government company.
See publication for full funding statement.
The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U. S. Department of Health and Human Services.
This publication does not represent the views of the Department of Veterans Affairs or the United States Government.
© 2018, The Author(s), under exclusive licence to Springer Nature America, Inc.